LAKE FOREST, CA – June 23, 2014 – Cryoport, Inc. (OTCBB: CYRX) (“the Company”) today announced that it has been chosen by Immudex to support its global distribution of biological materials and samples for proficiency panels to and from Immudex’s production and research facilities and customers.
Immudex, based in Denmark and with North American operations in Virginia, provides a comprehensive portfolio of high quality products and services for the immunotherapy and vaccine development community, including MHC Dextramer® reagents for the monitoring of antigen-specific T cells and conduction of the annual MHC Multimer and Elispot Proficiency Panels worldwide. Immudex’s goal is to enable simple, accurate and reproducible monitoring of antigen-specific T cells in scientific and clinical research, patient care, and to promote the routine use of these technologies in diagnostics, research, as well as vaccine and immunotherapy development. More about Immudex can be found at www.immudex.com
Liselotte Brix, Chief Operating Officer at Immudex, stated, “In our research and development we use patient blood samples, available in limited quantity. Cryoport’s solution allows transportation of these precious samples between us and collaborators without degradation of sample material. This ensures optimal sample usage and supports high quality research.”
Charlotte Halgreen, Proficiency Panel Coordinator at Immudex, stated, “We distribute cell samples for proficiency panel participants all over the world. Cryoport provides a complete solution, which includes logistics handling and shipment in temperature controlled dry vapor shippers, which allow consistent shipment conditions. This collaboration ensures a smooth and on-time delivery of uniform samples.”
“We are pleased to be working with Immudex,” stated Jerrell Shelton, Chief Executive Officer of Cryoport. “Using our unique Cryoport Express® liquid nitrogen dry vapor shippers, Cryoportal™ logistics management technology, and unparalleled logistics expertise providing monitoring and intervention capability, we believe Immudex will benefit significantly from Cryoport’s solutions. Our advanced cold chain logistics solutions are gaining traction in more and more life sciences companies who want reliable and economic solutions for their cold chain logistics challenges. We are proud to support leading, forward-thinking life sciences companies, such as Immudex, around the world.”
About Cryoport, Inc.
Cryoport provides leading-edge cryogenic logistics solutions to the life sciences industry through the combination of purpose-built proprietary packaging, information technology and specialized cold chain logistics expertise. Its competencies range from skilled, total turnkey management of the entire cold chain logistics process to complex total management solutions for outsourced cold chain logistics.
Its packaging, built around its Cryoport Express® liquid nitrogen dry vapor shippers, is validated to maintain a constant -150°C temperature for a 10-plus day dynamic shipment duration. Its information technology boast its Cryoportal™ Logistics Management Platform which manages the entire logistics process, including initial order input, document preparation, customs document preparation and clearance, integrator/courier management, shipment tracking, issue resolution, intervention, when necessary, and delivery. Cryoport uses recyclable and reusable components providing an environmentally friendly solution. Cryoport solutions can record the “chain of condition” and “chain of custody” for shipments thereby meeting the exacting requirements for scientific work and for regulatory purposes. For more information, visit www.cryoport.com.
Forward Looking Statements
Statements in this press release which are not purely historical, including statements regarding Cryoport, Inc.’s intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. It is important to note that the company's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, risks and uncertainties associated with the effect of changing economic conditions, trends in the products markets, variations in the company's cash flow, market acceptance risks, and technical development risks. The company’s business could be affected by a number of other factors, including the risk factors listed from time to time in the company's SEC reports including, but not limited to, the annual report on Form 10-K for the year ended March 31, 2013. The company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Cryoport, Inc. disclaims any obligation, and does not undertake to update or revise, any forward-looking statements in this press release.
Cryoport ContactsTodd Fromer / Garth Russeltfromer@kcsa.com / firstname.lastname@example.orgP: 1-212-682-6300